While further study and development of STAT3 inhibitors are needed, based on the promising pre-clinical results and evidence of activation in AML, STAT3 inhibition warrants further evaluation in clinical trials in leukemia. This evidence concerns the gene STAT3 and acute myeloid leukemia.